Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.


Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2021
Historique:
received: 13 08 2020
accepted: 07 11 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 30 1 2021
Statut: epublish

Résumé

The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system. The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities. The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.

Identifiants

pubmed: 33442247
doi: 10.2147/IJN.S275808
pii: 275808
pmc: PMC7797358
doi:

Substances chimiques

Antineoplastic Agents 0
Biocompatible Materials 0
Drug Carriers 0
Phenylurea Compounds 0
Piperidines 0
Protein Kinase Inhibitors 0
Quinazolines 0
Quinolines 0
Ferritins 9007-73-2
Folic Acid 935E97BOY8
lenvatinib EE083865G2
vandetanib YO460OQ37K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-14

Informations de copyright

© 2021 Skubalova et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Cell Physiol Biochem. 2019;53(5):805-819
pubmed: 31670920
Theranostics. 2020 Jan 1;10(2):687-706
pubmed: 31903145
BMC Cancer. 2019 Jan 8;19(1):41
pubmed: 30621641
J Pharm Sci. 2000 Nov;89(11):1452-64
pubmed: 11015690
Nat Chem Biol. 2012 Nov;8(11):941-8
pubmed: 23001032
Methods Cell Biol. 2019;153:69-92
pubmed: 31395385
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
Ann Oncol. 2004 May;15(5):786-92
pubmed: 15111348
Clin Cancer Res. 2018 Oct 15;24(20):5098-5111
pubmed: 30068707
Adv Healthc Mater. 2015 Jun 24;4(9):1305-10
pubmed: 25973730
ACS Nano. 2013 Aug 27;7(8):6988-96
pubmed: 23829542
Mol Cancer Res. 2009 Oct;7(10):1736-43
pubmed: 19808904
Cancer Cell Int. 2017 May 19;17:56
pubmed: 28533703
J Clin Invest. 2015 May;125(5):1780-9
pubmed: 25932675
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3653-8
pubmed: 12634425
Theranostics. 2021 Jan 1;11(4):1546-1567
pubmed: 33408767
J Pharmacol Exp Ther. 2007 May;321(2):462-8
pubmed: 17289839
Biomacromolecules. 2011 May 9;12(5):1629-40
pubmed: 21446722
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
Sci Rep. 2019 Nov 28;9(1):17755
pubmed: 31780685
Nat Nanotechnol. 2013 Feb;8(2):137-43
pubmed: 23334168
Int J Biol Macromol. 2019 Apr 1;126:1099-1111
pubmed: 30605747
Nanomedicine (Lond). 2014 Jul;9(14):2233-45
pubmed: 25405799
Nanoscale. 2015 Apr 21;7(15):6527-33
pubmed: 25786779
J Control Release. 2020 Sep 10;325:176-190
pubmed: 32619748
J Clin Endocrinol Metab. 2019 Mar 1;104(3):779-784
pubmed: 30383218
Sci Rep. 2017 Nov 24;7(1):16271
pubmed: 29176733
PLoS One. 2017 Apr 18;12(4):e0176015
pubmed: 28419132
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13872-7
pubmed: 16950881
Curr Opin Chem Biol. 2009 Jun;13(3):256-62
pubmed: 19419901
Cancer Res. 2002 Dec 15;62(24):7284-90
pubmed: 12499271
PLoS One. 2018 Jul 31;13(7):e0200302
pubmed: 30063723
ACS Nano. 2018 May 22;12(5):4408-4418
pubmed: 29723464
Oncogene. 2000 Nov 20;19(49):5690-701
pubmed: 11114749
Curr Hematol Malig Rep. 2016 Apr;11(2):71-9
pubmed: 26922746
Cells. 2019 Oct 07;8(10):
pubmed: 31591302
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18182-7
pubmed: 19011101
J Cancer Res Clin Oncol. 2015 May;141(5):769-84
pubmed: 25005786
Am J Physiol Cell Physiol. 2006 Sep;291(3):C445-55
pubmed: 16611735
Cancer Treat Rev. 2016 Jan;42:47-55
pubmed: 26678514
Nature. 2004 Nov 18;432(7015):294-7
pubmed: 15549090
J Am Coll Cardiol. 2015 Sep 8;66(10):1160-78
pubmed: 26337996
Nat Rev Cancer. 2002 Feb;2(2):143-8
pubmed: 12635177
Blood. 2011 Feb 24;117(8):e75-87
pubmed: 20810928
J Colloid Interface Sci. 2019 Mar 1;537:20-27
pubmed: 30415098
Mol Pharmacol. 2004 Jan;65(1):181-95
pubmed: 14722250
Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3673-3683
pubmed: 26980693
Chem Sci. 2017 Dec 18;9(4):790-810
pubmed: 29675145
Cancer Treat Rev. 2015 May;41(5):412-22
pubmed: 25818541
Sci Rep. 2018 Jun 11;8(1):8867
pubmed: 29891921
Toxicology. 2019 May 1;419:40-54
pubmed: 30914192
Biophys J. 2003 Apr;84(4):2256-63
pubmed: 12668434
Drugs. 2019 Apr;79(6):665-674
pubmed: 30993651
Neoplasia. 2003 Nov-Dec;5(6):495-506
pubmed: 14965443
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537
Dalton Trans. 2017 Oct 17;46(40):13690-13694
pubmed: 28971191
ACS Appl Mater Interfaces. 2016 Jun 15;8(23):14430-41
pubmed: 27219717

Auteurs

Zuzana Skubalova (Z)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.

Simona Rex (S)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.

Martina Sukupova (M)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.

Martin Zahalka (M)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.

Petr Skladal (P)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Jan Pribyl (J)

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Hana Michalkova (H)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.

Akila Weerasekera (A)

Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Vojtech Adam (V)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.

Zbynek Heger (Z)

Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH